JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $4 price target.
August 15, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies has received a reiterated Market Outperform rating and a maintained $4 price target from JMP Securities.
The reiterated Market Outperform rating and maintained $4 price target by JMP Securities indicates a positive outlook for Taysha Gene Therapies. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100